Ovarian Cancer Therapeutics Market Size, Share & Industry Analysis, By Drug Class (PARP Inhibitors, Platinum-based Chemotherapy, Taxanes, VEGF/Anti-angiogenic Agents, and Antimetabolites), By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, and Hormone Therapy), By Disease Indication (Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Germ Cell Ovarian Tumors, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and Others), and Regional Forecast, 2026-2034.

Last Updated: July 15, 2026 | Format: PDF | Report ID: FBI118232

Buy Now

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 6.71% from 2026-2034
Unit	Value (USD Billion)
Segmentation	By Drug Class, Therapy, Disease Indication, Route of Administration, Distribution Channel, and Region
By Drug Class	PARP Inhibitors Platinum-based Chemotherapy Taxanes VEGF / Anti-angiogenic Agents Antimetabolites Anthracyclines & Topoisomerase-targeting Agents Others
By Therapy	Chemotherapy Immunotherapy Targeted Therapy Hormone Therapy Others
By Disease Indication	Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer Germ Cell Ovarian Tumors Sex Cord-Stromal Tumors Others
By Route of Administration	Oral Parenteral
By Distribution Channel	Hospital Pharmacies Specialty Pharmacies Retail Pharmacies Others
By Region	North America (By Drug Class, Therapy, Disease Indication, Route of Administration, Distribution Channel, and Country) U.S. Canada Europe (By Drug Class, Therapy, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug Class, Therapy, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug Class, Therapy, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, Therapy, Disease Indication, Route of Administration, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa